

CURRICUM VITAE

Gregers Gautier Hermann

Chief Urologist, general surgeon

MD, DM Sc, Fellow of the European Board of Urology

Diploma of Public Administration (Health Management)

Denmark

2011

Gregers Gautier Hermann, MD, DM Sci.
Date of birth: March 13, 1958, 52 years old

Private address:

Langs Hegnet 59C, DK-2800 Lyngby
Denmark
Telf: (+45)4593-0134
Fax: (+45)45871110

Hospital address:

Dept of Urology
Rigshospitalet / Frederiksberg hospital
Copenhagen University
DK- 2000 Frederiksberg

MEDICAL DEGREES AND EXAMINES

Graduated Medical School (M.D) Copenhagen University: Summer 1983
D.M. Sci., Copenhagen University: October 1993
Danish accreditation in General Surgery: June 1997
Passed written assessment of the European Board Examination in Urology: Nov 1998
Danish accreditation in Urology: March 1999
12. months course in medical quality assurance. 1999
Norwegian accreditation as medical doctor (MD): April 1999
Fellow of the European Board of Urology (FEBU): June 1999
Diploma of Public Administration (Health Management): 2002-2004

PREVIOUS EMPLOYMENTS:

Gentofte Hospital. Surgical Gastroenterology. 1.7.-31.10.1983: Registrar.....	4 months
Herlev Hospital. Surgical Gastroenterology 1.11-31.6.1985: Registrar.....	19 months
Herlev Hospital. Medical Gastroenterology 1.7. -31.12.1985: Registrar	6 months
Herlev Hospital. Orthopaedic Surgery 1.1. -30.6.1986: Registrar.....	6 months
Herlev Hospital. Urology 1.7.1986 - 31.12.87: Registrar.....	18 months
The Fibiger Institute, dept of Tumor Cell Biology, Danish Cancer Society, dept of Oncology and dept of Urology Herlev Hospital 1.1.1988 - 31.12.1991: Research Fellow.....	48 months
Glostrup Hospital. Gynaecology 1.1.-30.6.1992: Registrar.....	6 months
Gentofte Hospital. Thoracic Surgery 1.7.1992-31.3.1993: Registrar.....	9 months

Herlev Hospital. Urology 1.4.1993-31.12.1993: Registrar.....	9 months
Herlev Hospital.Surgical Gastroenterology 1.1.1994-30.11.1994: Registrar.....	11 months
Glostrup Hospital. Surgical Gastroenterology 1.12.1994-31.8.95: Senior Registrar.....	9 months
Herlev Hospital. Urology 1.9.1995-31.8.1996: Senior Registrar.....	12 months
Glostrup Hospital. Urology 1.9.1996-31.8.1997: Senior Registrar.....	12 months
Herlev Hospital. Nephrology 1.9.1997-28.2.1998: Registrar.....	6 months
Herlev Hospital. Urology 1.9.1997-31.12.1999: Fellow.....	24 months
Mater Hospital, Australia, urology dep 1.1.2000-1.1.2001: Urolog fellow.....	12 months
Frederiksberg hospital, Cph university, Urol. dep 1.2.2001-31.8.2001: Urology fellow.....	7 months
Rigshospitalet, Cph university 1.9.2001-28.2.2003 : Urology fellow.....	18 months

PRESENT EMPLOYMENT:

Frederiksberg hospital, Cph university, Urol. Dep (and part time Rigs Hospitalet, Cph)
Chief Urologist since 1.3.2003

EMPLOYMENT IN AUSTRALIA:

To learn more about urooncology and adult and children urology I achieved 12 months employment as senior fellow at a university department at Mater Hospital, Brisbane, Australia, urology dep. During the employment I had contact with Institute for Tumorbiology and Immunology (chairman Derek Hart) regarding immunological treatment of cancer.

EMPLOYMENT IN LAB

For 4 years I was full time research fellow at Fibiger Instituttet, dept. of Cellebiology and Cancer, Danish Cancer Society. The first 2 years I was also associated to dept of Oncology and Urology at Herlev Hospital, Cph. Techniques: Cell culture, monoclonal antibodies, cr51-release assays, cell separation using monoclonal antibodies.

CONSULTANT EMPLOYMENTS:

1: June 1991- 1. January 2010: Consultant in the Danish Research Council

2: August 1991-31.12.1993: Part time consultant in Medical Department, LEO Pharmaceutical Company (15 hours/week)

3: July 1991: Danish Medical Association. Performed report regarding: "Postgraduat EDP-education

4: 1995: Danish Medical Journal. Performed report evaluating the statistical, metodological level in the Danish Medical Journal

5: 1996 - : Danish national Bladder Cancer Registry (DBCR). I have developed DBCR and is chairman of DBCRs manager-group.

6: 2002-: Ferring Pharmaceuticals. Evaluation of new methods for diagnosis and treatment of superficial bladder cancer.

INTERNATIONAL AND NATIONAL OFFICIAL MEDICAL ENGAGEMENT:

21-23. marts 1989. OECI (Organisation of European Cancer Institutes). Evaluation of the Italian INTERLAB-databases (Re. molecular- and cell biology) placed at Instituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

Summer 1994-: member of the Bladder Cancer Group in Nordic Urological Society representing the Danish Urological Society.

March 1996-: Elected for European Society of Residents in Urology (ESRU) as 1 of the 2 Danish delegates.

March 1996-: Elected for the board of the Danish Urological Science Club (DUSC), encompasses residents in urology and urologists in Denmark, who have not yet been chief urologists).

Summer 1996-1. January 2000: Chairman of Danish Urological Science Club (DUSC)

September 1996: Member of the Manpower committee of the European Board of Urology (EBU) representing European Society of Residents in Urology (ESRU).

1996: Chairman of a working group in Danish Urological Society developing a national database of all patients with bladder in Denmark.

1998: European Board of Urology (EBU) and European Association of Urology (EAU). Member of the European Scholar Ship Program (EUSP) representing ESRU.

Summer 1998: Chairman of the scientific committee of the ESRU, which prepared the congress meeting of ESRU, held in cooperation with the European Association of Urology (EAU) congress in Stockholm 1999.

January 2000-January 2001: urology clinical fellow, Urology department, Mater Hospital, Brisbane, Chairman: Roger Watson

2002-2005: Danish Urological Association. Member of working group defining the guidelines for treatment of bladder cancer in Denmark

2004: Danish Urological Association. Member of a working group defining how future research in urooncology in Denmark are being structured

2005-2010: Secretary of working group to define future structure of research in Danish Urooncology

2005-: Member of the multidisciplinary Danish Renal Cancer Group (DARENCA)

2005-2010 Chairman of the multidisciplinary Danish Bladder Cancer Group (DaBlaCa)

2010- Member of the multidisciplinary Danish Bladder Cancer Group (DaBlaCa)

2008-: Member of Scientific Council, Frederiksberg hospital

PHD evaluation: referee on cand.scient. Pia Pinholt Munksgaards phd: Identification and characterization of prognostic and predictive markers in bladder cancer

SCIENTIFIC WORK:

- 1: Primary hemangiosarcoma of the spleen with angioscintigraphic demonstration of metastases. Hermann GG, Fogh J, Græm N, Hansen OP, Hippe E. Cancer, 53:1682-1685, 1984.
- 2: Salazosulfapyridin-induceret hemiparese. (A case-report). En ikke tidligere beskrevet bivirkning af salazosulfapyridin behandling af Mb. Crohn. Hermann GG, Struckmann J. Ugeskrift for læger (Danish Medical Journal) 146:2562 - 2563, 1984.
- 3: (Unrecognized cystadenoma pancreatis). Miskendt cystadenoma pancreatis. Hermann GG & Baden HH. Ugeskrift for læger (Danish Medical Journal) 148:1477-8, 1986.
- 4: Cystis glandulae suprarenalis. (Three cases and a review). Beskrivelse af tre tilfælde og gennemgang af litteraturen. Bagi P, Hermann GG, Burcharth F. Ugeskrift for Læger (Danish Medical Journal) 148:2357, 1986.
- 5: Hospitalslægers anvendelse af edb (Hospital doctors use of EDP). En spørgeskemaundersøgelse. Hermann GG, Bruun P, Billesbølle P, inspektoratet KAS Herlev. Ugeskrift for læger (Danish Medical Journal) 1986;148:3479-3480.
- 6: Early secondary suture versus healing by second intention of incisional abscesses. Hermann GG, Bagi P, Christoffersen I. Surgery, Gynecology and Obstetric. 1988;167:16-18.
- 7: Holdt cimetidin hvad vi lovede. (Was Cimetidine as good as thought?). En efterundersøgelse af cimetidins terapeutiske effekt på ventrikel ulcera. Hermann GG, stud.med Jacobsen K og stud.med Homann C. Ugeskr læger (Danish Medical Journal) 1987;149:1198.
- 8: Assessment of pain: A comparison between patients and doctors. Forrest M, Hermann GG, Andersen B. Acta Anaesthesiol Scand 1989;33:255-256.
- 9: (Scientific papers in Danish Medical Journal during 25 years. An evaluation of the design). Videnskabelige artikler i Ugeskriftet gennem 25 år: Artikeltype og forsøgsdesign. Jørgensen PE, Forrest M, Hermann GG, Gøtzsche PC, Bjørn Andersen. Ugeskr Læger (Danish Medical Journal) 1989;151:218-220.
- 10: (Scientific papers in Danish Medical Journal during 25 years. An evaluation of the results). Videnskabelige artikler i Ugeskriftet gennem 25 år: analyse og fortolkning af forsøgsresultater. Gøtzsche PC, Forrest M, Jørgensen PE, Hermann GG, Bjørn Andersen. Ugeskr Læger (Danish medical Journal) 1989;151:220-222.
- 11: Defect in lectin-induced interleukin 2 production by peripheral blood lymphocytes of patients with invasive urinary bladder carcinoma. Bubenik J, Kieler J, Tromholt V, Hermann G, Jandlova T. Immunology Letters 1988;18:115-118.
- 12: (Research methodology) Forskningsmetodologiske lærestykker.3. Ringslutningen. Hermann GG. Ugeskr Læger (Danish Medical Journal). 1989;151:397.
- 13: The effect of LAK cells and recombinant interleukin-2 in advanced bladder cancer: an experimental and clinical study. Steven K, Geertsen P, Hermann G, Tromholt V, Kieler J, von der

Maase H, Van der Plas, Palmer P, Franks CR. Cancer Treatment Reviews 1989;16 (Supp A), 173.

14: Voiding patterns in men evaluated by a questionnaire survey. Sommer P, Bauer T, Hermann GG, Nielsen KK, Kristensen ES, Steven K, Nordling J. Br. J Urol. 1990;65:155-160.

15: Voiding patterns and prevalence of incontinence in women. A questionnaire survey. Sommer P, Bauer T, Hermann GG, Nielsen KK, Kristensen ES, Steven K, Nordling J. Br. J. Urol.1990;66:12-15.

16: (Interleukin-2 treatment of cancer diseases. A review). Interleukin-2 baseret immunterapi af kræftsygdomme. Geertsen P, Hermann GG, Claësson MH, Steven K, Zeuthen J, von der Maase H. Ugeskr Læger (Danish Medical Journal) 1990;152:3513-3517.

17: Low dose intravesical heparin as profylaksis against recurrent noninvasive stage (Ta) bladder cancer. Bitsch, M., Hermann, G.G., Andersen, J.P., Steven, K. J. Urol. 1990;144:635-636.

18: Intravesical BCG therapy in bladder carcinoma: Effect on cytotoxicity, IL-2 production and phenotype of peripheral blood mononuclear cells. Hermann G.G., Petersen K.R., Steven K., Zeuthen J. Scand. J. Urol and Nephrol 1991;25:269-273.

19: Reduced LAK-cytotoxicity of peripheral blood monocular cells in patients with bladder cancer: Decreased LAK cytotoxicity caused by a low incidence of CD56⁺ and CD57⁺ monocular blood cells. Hermann G.G., Petersen K.R., Steven K., Zeuthen J. J. Clin Immunol. 1990;6:311-320.

20: LAK cell mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2. Cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines. Hermann G.G., Zeuthen J., Claësson M.H.. Nat. Cell Growth Regul. 1992;11:7-16.

21: Interleukin-2 dose, monocytes and CD25⁺ lymphocytes as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma. Hermann, G.G., Geertsen, P., von der Maase, H., Zeuthen J. Cancer, Immunol. Immunother. 1991;34:111-114

22: A phase II trial of recombinant interleukin-2 by continuous infussion in advanced renal cell carcinoma. Geertsen, P., Hermann, G.G., Steven, K., von der Maase, H. J Clin Oncol 1992;10:753-759.

23: Interleukin-2 and LAK cell treatment of advanced bladder cancer: Clinical results and immunological effects. Hermann, G.G., Geertsen P., Steven, K., von der Maase, H., Andersen C, Hald, T. Zeuthen J. Cancer Res. 1992; 52:726-733.

24: Monocyte production in vitro of IL-1, IL-6 og TNF in patients with renal cell carcinoma treated with rIL-2. Hermann, G.G., Zeuthen, J., Geertsen P.F., Claësson M.H. Cytokine 1992;4:144-150.

25: Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Spruck III,

CH, Rideout WM, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, Nichols PW, Horn T, Hermann GG, Steven K, Ross RK, Yu MC, Jones PA. Cancer Res 1993;53:1162-1166

26: Distinct genetic defects distinguish carcinoma in situ from papillary tumors of the bladder. Spruck III CH, Gonzalez-Zulueta M, Esrig D, Ohneseit PF, Miyao N, Tsai YC, Cote R, Dubeau L, Nichols PW, Hermann GG, Horn T, Steven K, Skinner DG, Jones PA. New Eng J Med. 1993;

27: Microsatellite instability in bladder cancer. Gonzalez-Zulueta M, Ruppert JM, Tokino K, Tsai YC, Spruck III CH, Miyao N, Nichols PW, Hermann GG, Horn T, Steven K, Summerhayes IC, Sidransky D, Jones PA. Cancer Res; 1993;53:5620-5623

28: The in vitro cytotoxicity of urine from patients with interstitial cystitis. Beier-Holgersen R, Hermann GG, Mortensen SO, Steven K. J Urol 1994;151:206-207.

29: Transfection of glioma cells with neural cell adhesion molecule NCAM: Effect on glioma cell invasion and growth in vivo. Edvardsen K, Pedersen P, Bjerkvig R, Hermann GG, Zeuthen J, Laerum OD, Walsh FS, Bock E. Cancer Res

30: Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma. Hermann GG. Disp. APMIS 1993;101:1-26 (supp 35).

31: Vitamin D receptors in transitiocellular bladder cancer. Hermann GG, Andersen CB. Scand J Urol Nephrol. 1997;31(2):161-6.

32: The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. Hermann GG, Horn T, Steven K. J Urol. 1998;159(1):91-4.

33: Education of Urologists and General Surgeons in Queensland, Australien. Hermann GG. Ugeskr Læger (Danish Medical Journal). 2001 Jun 25;163(26):3655-6

34: Nye behandlinger ved urologiske kræftsygdomme. Lund L, Borre M, Hermann GG, Svolgaard N. Ugeskr Læger 2008;170(12):1057

35: Granulomatous epididymo-orchitis, a rare complication of intravesical baccillus Calmette-Guérin therapy for urological cancer. Harving SS, Asmussen L, Roosen JU, Hermann GG

36: Fluorescence guided TUR-B reduces bladder tumour recurrence due to less residual tumour tissue after TURB in Ta/T1 patients. A randomised 2-center study. Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun D. 2010. In press for Br J Urol Int

37: Low ANXA10 expression is associated with disease aggressiveness in bladder cancer. Munksgaard PP¹, Mansilla F¹, Eskildsen AB¹, Frstrup N¹, Birkenkamp-Demtrøder K¹, Uihøj BP², Borre M³, Agerbæk M⁴, Hermann GG⁵, Ørntoft TF¹, Dyrskjøt L¹. Submitted for Cancer Res.

SCIENTIFIC MANUSCRIPTS IN PREPARATION:

1: Photo Dynamic Diagnosis and results of biopsies in flexible cystoscopy of bladder tumor

patients in an out patient department. Hermann GG, Mogensen K, Pedersen HM, Toft BG for Endourol. 50 patients included. Patient inclusion ends about June 2011.

2: The influence on quality of life of transurethral resection of bladder tumour (TURB) in patients with non-muscle invasive bladdercancer. Mogensen K, Hermann GG. Study start 1. March 2011.

PROJECTS FOR MY MEDICAL THESIS: 29. October 1993, Copenhagen University.

Title:

Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.

Projects:

1: LAK cell mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2. Cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines. Hermann G.G., Zeuthen J., Claësson M.H.. Nat. Cell Growth Regul. 1992;11:7-16.

2: Reduced LAK-cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: Decreased LAK cytotoxicity caused by a low incidence of CD56⁺ and CD57⁺ mononuclear blood cells. Hermann G.G., Petersen K.R., Steven K., Zeuthen J.. J. Clin Immunol.;1990;6:311-320.

3: Monocyte production *in vitro* of IL-1, IL-6 og TNF in patients with renal cell carcinoma treated with rIL-2. Hermann, G.G., Zeuthen, J., Geertsens P.F., Claësson M.H. Cytokine 1992;4:144-150.

4: Interleukin-2 dose, monocytes and CD25⁺ lymphocytes as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma. Hermann, G.G., Geertsens, P., von der Maase, H., Zeuthen J. Cancer, Immunol. Immunother. 1991;34:111-114

5: A phase II trial of recombinant interleukin-2 by continuous infusion in advanced renal cell carcinoma. Geertsens, P., Hermann, G.G., Steven, K., von der Maase, H. J Clin Oncol 1992;10:753-759.

6: Interleukin-2 and LAK cell treatment of advanced bladder cancer: Clinical results and immunological effects. Hermann, G.G., Geertsens P., Steven, K., von der Maase, H., Andersen, C., Hald, T., Zeuthen J. Cancer Res. 1992;52:726-733.

Projects related to but not included in the thesis:

7: Intravesical BCG therapy in bladder carcinoma: Effect on cytotoxicity, IL-2 production and phenotype of peripheral blood mononuclear cells. Hermann G.G., Petersen K.R., Steven K., Zeuthen J. Scand. J. Urol and Nephrol. 1991; 25: 269-273.

8: Defect in lectin-induced interleukin-2 production by peripheral blood lymphocytes of patients with invasive urinary bladder carcinoma. Bubenik J., Kieler J., Tromholt V., Hermann G., Jandlova T.. Immunol Let. 1988;18:115.

9: The effect of LAK cells and recombinant interleukin-2 in advanced bladder cancer: An experimental and clinical study. Steven K., Geertsens P., Hermann G., Tromholt V., Kieler J., von der Maase H., van der Plas J., Palmer P., Franks C.R.. Cancer Treatm. Rev. 1989; 16 (Suppl. A.),173.

10: (Interleukin-2 based immunotherapy of cancer diseases). Interleukin-2 baseret immunterapi af kræftsygdomme. Geertsens P, Hermann GG, Claësson MH, Steven K, Zeuthen J, von der

Maase H. Ugeskrift for Læger (Danish Medical Journal) 1990;152:3513-3517.

NATIONAL PRINCIPAL INVESTIGATOR IN FOLLOWING STUDIES:

1): Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RTD, Mardiak J, Hussain T, Sylvester R, Parmar MKB, Royston P, Mulders PFA. Lancet. 2010; 375: 641-648

2): A phase III randomised double-blind study comparing sorafenib with placebo in patients with resected primary renal cell carcinoma at high or intermediate risk of relapse". The SORCE study. A MRC/EORTC study.

POSTERS:

Nursing Care in relation to Implementation of Immunological Treatment of Cancer of the Kidney in the Urological Unit. Holm GB, Højer M, Bagi P, Hermann GG. Nordic Urological Association (NUF) 2005

PROJECTS PERFORMED DURING EMPLOYMENT IN PHARMACEUTICAL INDUSTRY:

1: Comparative study of calcipotriol ointment in combination with uvb phototherapy and calcipotriol ointment alone in the treatment of psoriasis vulgaris (pp. 0-120). Hermann, GG, Jürgensen, HJ. Internal study report.

2: The tolerability and efficacy of KH1060 ointment in atopic dermatitis (pp. 0-100). Hermann, GG, Jürgensen, HJ. Internal study report.

3. Bayer Schering pharma Expert Symposium on Target Therapies. Vienna, November 16-18. 2007

OTHER MEDICAL REPORTS:

1): Bladder Cancer Registry (BCR). 8 years continuous registration of patients with bladder cancer from 2 Danish Urological Departments. A clinical study report. Hermann GG, Horn T, Steven K and the Bladder Cancer Group at Herlev Hospital, Skejby Hospital and Statistical Research Unit, the Panum Institute, Copenhagen University

2: Yearreport 2003 for Danish Bladder Cancer Registry, - Analyses of the first 4 years.. Hermann GG, DBCR. See: <http://www.urologi.dk/sektioner/DBCR/DBCR-index.htm>.

HEALTH ECONOMIC REPORTS:

Economic consequences of changed bladder tumor treatment. Hermann GG, Pedersen TW, Gregersen D, Jørgensen T. 2004. Project, Diploma of Public Administration

BOOKS:

1: (Computers and biological research. An introduction)."Edb og biologisk forskning. En

Curriculum vitae, Gregers G Hermann

introduktion". Raabye P og Hermann GG. Munksgaards forlag 1989.

2: "Renal tumors" in "Klinisk kompendium" (the Danish surgical textbook), 2001

3: "Transitocellular tumors" in "Klinisk kompendium" (the Danish surgical textbook), 2001

BOOK REVIEWES:

Surgical Intuition. What it is and how to get it. Charles M Abernathy and Robert M Hamm. 1995. Philadelphia: Hanley & Belfus/Mosby, 434pp. Hilden J, Hermann GG

Surgical Scripts. Master surgeons think aloud about 43 common surgical problems. Charles M Abernathy and Robert M Hamm. 1994. Philadelphia: Hanley & Belfus/Mosby, 196pp. Hilden J, Hermann GG

ATTENDED COURSES:

1: Research methodology in epidemiology and social medicine IV. Teachers: Finn Kamper-Jørgensen, Olaf Bonnevie and Finn Gyntelberg. March 1982.

2: How to write and publish scientific articles. the Medical Faculty, Copenhagen by Nils Axelsen, Keld Danø og Povl Riis. 28-30 March 1984.

3: Course in medical research methodology. Copenhagen University and the Danish Medical Society by F. Güttler, B. Andersen, O. Bonnevie, P. Riis, H.R. Wulff. 2-4 November and 23-25 November 1984.

4: Course in clinical microbiology. Danish Medical Society. 14-15 February 1985.

5: Basis course in electronic search of information by EDP. Danish DIANE (Direct information Access Network for Europe) Center. Danish Technical University. 27. February 1985.

6: Electronical search of information by microcomputers. Danish DIANE Center. Danish Technical University. 28. February 1985.

7: " Introduction to VM/CMS". A computerlanguage for mainframes. NEUCC (North European Computer Center). 16-19 April 1985.

8: Wound healing. 5. september 1985. Copenhagen University, Herlev Hospital.

9: How to plan a clinical randomized study. 10-11 January 1986. Copenhagen Medical Society

10: Qualitative research methods and their theoretical basis. 20-22 April 1986. Copenhagen Medical Society and Copenhagen University.

11: Course in the computer language Pascal. 28 September-7 October 1986. RECKU (Regional EDP-Center at Copenhagen University).

12: Course in basical epidemiological method with regard to clinical and epidemiological research. 28-30 November 1986. Aarhus Universitet by Anders Foldspang and Michael Væth.

- 13: Course in epidemiological method (advanced course) with regard to clinical and epidemiological research. 22-24 January & 4-6 March 1988. Aarhus University Institute of Social Medicine, Anders Foldspang, Svend Juul, Jørn Olsen, Svend Sabroe.
- 14: Course in qualitative research. 1.-2. & 27.-28. November 1987. Institute of General medicine, Copenhagen Universitet Paul Backer
- 15: Gynecology and Urology. 19-20 November 1987. Danish Society of Urology and Danish Society of Obstetrics and Gynecology.
- 16: Course in immunological techniques. 25-28 April 1988. Copenhagen University.
- 17: Course in statistical computer language SAS. June-September 1991. University center UNI-C, Aarhus/Copenhagen).
- 18: Pharmaceutical Society. Clinical studies of medicaments. Mondays from March 1 to 5. April 1993.
- 19: Wounds and woundhealing. 11-13. oktober 1993. Plastiksurgical Department Herlev Hospital. Chairman Christen Krag
- 20: Kidney stone and Urological Endoscopy. 25-27. October 1993. Rigshospitalet. Chairman Jørgen Kvist Kristensen.
- 21: Operative Surgery, "hands-on" practical course 22-26 November 1993. The Panum Institute. Copenhagen University. Chairman Finn Gottrup
- 22: Surgical Pathophysiology. 24-26. January 1994. Copenhagen University. Chairman Kåre Sander-Jensen
- 23: Clinical Microbiology. 7-11 March 1994. Copenhagen University. Chairman Henrik Friis
- 24: Diseases of the breast 14-16 March 1994. Rigshospitalet. Chairman Mogens Blichert-Toft
- 25: Medical and Surgical Gastroenterology. May 2-5, 1994. Copenhagen University. F.W.Henriksen & O.B.Schaffalitzky de Muckadell
- 26: Course in medical administration. September 5-7, 1994. Danish Ministry of Health. Chairman Steen Levin Nielsen
- 27: Scandinavian Association of Digestive Endoscopy. 13. SADE course. "Hands on" practical course. Marts 6-10, 1995
- 28: 1st Copenhagen Update on European Urology 28-31. May 1996. Rigshospitalet.
- 29: 11th Copenhagen Symposium on Endoscopic Urological Surgery. Herlev Hospital, Urological Dep. January 28-31, 1997.

30: Practical "hands on" course in Laparoscopic Gastroenterology. Royal Danish Veterinary School. April 16-17, 1997.

31: Perspectives in bladder cancer. Monte Carlo, Monaco. November 16-17

32: GCP in clinical cancer research. Danish Cancer organisation, SKA. September 18-19, 2006

33: Urology Masterclasses in Laparoscopy. 12-13th January 2006. Tyco Healthcare

34: Third International Urological Workshop in Laparoscopy. Course in laparoscopy 2007, Madrid, Spain. 13-18. November 2007

35: Laparoscopic treatment of kidney tumours. IRCAD. April 24-26, 2008. Strasbourg, France

36: The Third European International Kidney Cancer Symposium. 2-3 May, 2008

37: Management in a political field. October 1-3th, 2008. Danish medical association

LECTURES/PAPERS:

1) Early secondary suture of ruptured surgical wounds. Hermann GG, Bagi P. 14. november 1985 Randers Hospital.

2) Adrenal cysts judged as hepatic and pancreatic cysts. P.Bagi, G.Hermann, L.Højgaard, F.Bendtsen, T.Sørensen, F.Burcharth. 28.november 1985. Danish Society of Gastroenterology.

3) Early secondary suture of surgical wounds. Hermann G, Bagi P. 20. januar 1986. Hvidovre Hospital.

4) "Microbiology in relation to early secondary wound suture. GG Hermann & dr. med. Ernø Gutschik. January 20, 1986. Hvidovre Hospital.

5) Paper no 3 and 4 repeated at Surgical Department, Roskilde Hospital.

6) 1987. Bladder tumors. Dynamic prognostic evaluation and management. Hermann G.G. & Steven K. 32. Computer workshop about Clinical Decision Analysis in Medical Care.

7) Lymphokin activated killer (LAK) cell therapy. Hermann GG. 21.9.1988. Rigshospitalet. Klaus Bendtzen, and Gunnar Bendixen, Biotechnology Center.

8) Adoptive immunotherapy with interleukin-2 of advanced kidney and bladder cancer. Hermann GG. 10.11.1988. Aarhus hospital. Prof. dr. med. B Nerstrøm.

9) First Interleukin-2 international symposium. Amsterdam. The effect of LAK cells and recombinant IL-2 in advanced bladder cancer: an experimental and clinical study. Steven K, Geertsen P, Hermann GG, Kieler J, Tromholt V. 11-12 november 1988.

- 10) Reduced immunological function and possibility of biological stimulation of the immune system. Zeuthen J, Tromholt V, Hermann GG. Workshop on cancer and immunology: biological and psychological aspects. Danish Cancer Society 25.Maj 1989.
- 11) IL-2 and LAK-cell therapy of renal cancer and bladder cancer. Hermann, G.G. Juli 1989. International Symposium at the Fibiger Institute.
- 12) The antitumor efficacy of human recombinant interleukin-2. Bubenik, J., Kieler, J., Tromholt, V., Hermann, G.G. Juli 1989. International Symposium at the Fibiger Institute.
- 13) Cytotoxicity and phenotype of peripheral blood mononuclear cells in patients with bladder cancer. Hermann, G.G., Petersen, K.R., Steven, K. Danish Society of Immunology, January 25,1990.
- 14) Immunological mechanisms and lymphocyte populations during interleukin-2 and LAK cell therapy. Hermann, G.G. Danish Society of Surgery. March 22, 1990.
- 15) Experience with the MACS (Magnetic Activated Cell Separation) system. Hermann, G.G. Danish Society of Flowcytometry 1990.
- 16) A Phase II trial of recombinant Interleukin-2 by continuous infusion in advanced renal cell carcinoma. Geertsen, P., Hermann, G.G., Steven, K. van der Maase, H. Danish Society of Cancer Research. Maj 4, 1990.
- 17) The cytotoxic effect of interleukin-2 activated lymphocytes (LAK cells) against T24 bladder carcinoma cells as compared to classical target cell lines. Hermann, G.G., Zeuthen, J. Danish Society of Cancer Research. Maj 4,1990.
- 18) The cytotoxic effect of interleukin-2 activated lymphocytes (LAK cells) against T24 bladder carcinoma cells as compared to classical target cell lines. Hermann, G.G., Zeuthen, J. XXIst meeting of the Scandinavian Society for Immunology. Stockholm, Sverige 11-14 June 1990.
- 19) A phase II trial of recombinant interleukin-2 by continuous infusion in advanced renal cell carcinoma. Geertsen, P., Hermann, G.G., Steven, K., Zeuthen, J. Hald, T., van der Maase, H. American Urological Association (AUA). May 1990.
- 20) Low dose intravesical heparin as profylaxis against recurrent non invasive transitional cell tumor. Bitsch, M., Hermann, G.G., Andersen, J.P., Hald, T., Steven, K. American Urological Association (AUA). May 1990.
- 21) Biological response modifiers: antineoplastic mechanisms with focus on IL-2. Hermann GG. Danish Cancer Society 3.10.1990.
- 22) What is required for a clinical registry for use in the clinic. Hermann.G.G. Danish Society of Medical Information. October 11,1990.
- 23) Immunotherapy in Urological cancer. Hermann GG. Danish Health Ministry, course in "Basic Urological Oncology. March 1,1991.

- 24) Interleukin-2 dose, monocytes and CD25⁺ lymphocytes as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma. Hermann, G.G., Geertsen, P., von der Maase, H., Zeuthen J. Danish Society of Cancer Research. May 3, 1991.
- 25) Expression of the adhesion molecule VLA-1 on peripheral blood and in tumors during IL-2 therapy. Hermann GG, Geertsen, PF, Andersen C, Zeuthen, J. VII international congress of Natural Killer cells. Stockholm, Sweden. July 1991.
- 26) The use of Red 613 in tripple fluorecence experiments. November 22,1991. Hermann GG. Danish Society of Flowcytometry. Copenhagen.
- 27) Transcriptional inactivation of P53 in human bladder tumor cells. Skouv J, Horn T, Steven K, Hermann GG, Forchhammer J. Danish Society of Cancer Research. May 1, 1992.
- 28) Monocyte production in vitro of IL-1, IL-6 og TNF in patients with renal cell carcinoma treated with rIL-2. Hermann, G.G., Zeuthen, J., Geertsen P.F., Claësson M.H.. 8th international congress of Immunology, 1992, Budapest, Hungary.
- 29) P53 mutation: An early event in the formation of transitional cell carcinoma-in-situ. Spruck, C.H. Esrig D. Gonzola M. Petra F. CA USA, Steven K. Horn T. Hermann G.G. Copenhagen, Cote R.J. Jones P.A. CA USA. American Urological Association. 1993 San Antonio. J Urol (Suppl) 1993;149:237A
- 30) p53 mutations in relation to tobacco use in bladder cancer. Olumi AF, Spruck CH, Rideout WM, Ohnesell PF, Yang AS, Tsai YC, Nichols PW, Horn T, Hermann GG, Steven K, Ross RK, Yu MC, Jones PA. American Urological Association 1993 San Antonio. J Urol (Suppl) 1993;149:238A
- 31) Distinct genetic defects distinguish carcinoma in situ from papillary tumors of the bladder. Gonzalez-Zulueta M, Spruck CH, Esrig D, Ohneseit P, Miyao N, Tsai Y, Cote R, Dubeau L, CA USA, Hermann GG, Horn T, Steven K. Copenhagen, Jones P.A. CA USA. AACR 1993.
- 32) Interleukin-2 terapy of advanced renal cell carcinoma and transitional cell bladder cancer. Hermann GG, Geertsen P, Zeuthen J, Von der Maase H, Andersen CB, Hald T, Steven K. Danish Society of Surgery 1994.
- 33) 2. international congress on intravesical BCG. Oslo, November 1996. Recording of data from patients with bladder cancer. Hermann GG
- 34) Urooncology meeting Brisbane, Australia,14. marts 2000. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. Hermann GG.
- 35) Mater Research Institute, Brisbane, 28. april 2000. Interleukine-2 and LAK cell treatment of patients with bladder and renal cancer. Hermann GG.
- 36) Danish Urology Association. 2001. Herlev hospital. A year as fellow at a Australasian

Urological department

37) Danish Urology Association. 2001. Herlev hospital. Danish Bladder Cancer Registry.

38) Immunological treatment of patients with metastatic renal cell carcinoma. Hermann GG. Institute for Tumor Biology. Mater hospital. Brisbane, Australien. Januar 2004. Invited speaker.

39) Danish Urology Association. 2004. Report about national plans about future research in Danish urooncology. Momsen S, Hermann GG

40) Bladder cancer in Denmark. Presentation of data from 4000 Danish patients with bladder cancer. Hermann GG.

41): Bladder Cancer European Interactive Forum 2009. Dublin, Ireland. Photo Dynamic Diagnosis and results of biopsies in flexible cystoscopy of bladder tumor patients in an out patient department. Hermann GG, Mogensen K, Pedersen HM, Toft BG

TEACHING:

1->20): **Performed 20 times**. 1-day computer (PC) course.

21->22): The use of computers in medical research. Chairman: Gregers G Hermann. Teachers: Gregers G Hermann, Peter Raabye, Kell Østerlind, Asger Dirksen, HR Wulff and staff from Copenhagen University Computer Center (UNI-C). 3-5 May and 8-10 November 1987

23->38): **Performed 16 times**. The use of computers in medical research. Chairman: Gregers G Hermann and Peter Raabye. Teachers: Gregers G Hermann, Peter Raabye. HR Wulff and Poul Schlichting. First time: 25-27 November 1988, last time 12-14. April 1996.

39->40): 1.3.1989 and 12.3.1990. IL-2 and LAK cell therapy. Danish Health Ministry, course in Medical Immunology. Hermann GG.

41-42): Immunotherapy in Urological cancer. Hermann GG. Danish Health Ministry and Danish Society of Urology 1.3.1991.

43): Computer facilities required for epidemiological research. Hermann GG. Danish Society of Gynecology. February 23, 1992.

44): The use of EDP in clinic and lab. Ph.D. course: Planning of clinical studies September 25, 1992. Chairman Misser Forrest.

45): "Immunotherapy of cancer. Course in Oncology. October 15, 1992. Copenhagen University, Chairman Mogens Spang-Thomsen.

46): Ph. D. course in "EDB in medical research" 3-6 November 1992, Copenhagen University. Chairman and teacher: Gregers G Hermann supplied by 7 other teachers (lawyer, surgeons, biochemistrists).

47->50): Ph.D. course "basis course in edp and medical research. Copenhagen University. Repeated March 2.-5, 1993, spring 1994 and fall 1995 and September 10-13, 1996. Chairman and teacher: GG Hermann. Teachers from Danish universities.

51): PC-facilities for Epidemiological Research. Hermann GG. Danish Society of Gynecology. February 28, 1993.

52): Computer course for GPs. Danish Medical Society. Spring 1994. Ø Lidegaard og GG Hermann

53): Ph.D. "basic course in EDP and medical science", November 8-11, 1994.

54): 11th Copenhagen Symposium on Endoscopic Urological Surgery. Participated in expert panel in workshops concerning bladder cancer. January 29-31, 1997

55): Chairman of the Danish course of Urology for trainees in Urology

Bladder Cancer European Interactive Forum 2006. Lisabon, Portugal. Chairman of workshop regarding bladder cancer.

Diagnosis of bladder cancer. Symposium. Nordic Urological Association (NUF) June 14, 2007. Aarhus, Denmark

Bladder Cancer European Interactive Forum 2008. London, UK. Chairman of workshop regarding bladder cancer.

April 30. 2007. Manager and chairman. Seminar: Fluorescence guided diagnosis and intravesical chemotherapy in non-invasive bladder tumours. Hermann GG.

Bladder Cancer European Interactive Forum 2009. Dublin, Ireland. Chairman of workshop regarding bladder cancer.

STUDY VISITS & ATTENDED CONGRESSES:

1)1.-4. April 1986. Study visit to Huddinge hospital, Stockholm University, medical department to see computerised diagnoses and treatment.

2) First interleukin-2 international symposium. Free university of Amsterdam. November 11-12, 1988

3) VI international congress of Natural Killer Cells. Goslar, Germany. July 26-29, 1989.

4) The biology and clinical application of IL-2. Sheffield University. October 23-25, 1989.

5) XXIst meeting of the Scandinavian Society for Immunology. Stockholm, Sweden June 1-14, 1990.

6) VII international congress of Natural Killer cells. Stockholm, Sweden. July 1991.

- 7) 8th International Congress of Immunology, Budapest, Hungary, August 24-28, 1992.
- 8) 2nd international congress on intravesical BCG. Oslo, November 1996.
- 9) EBU, ESU and ESRU symposium, Brüssel, May 15-17, 1997.
- 10) EAU and ESRU annual congress, Barcelona, 1998
- 11) EAU and ESRU annual congress, Stockholm, 1999
- 12) Australasian association of Urology, Sidney, 2000.
- 13) Urotelial Cancer. EORTC/EAU. September 2001, Monaco
- 14) Professor Martin Gore, Royal Marsden Hospital, London. September 2002. Study visit regarding immunological treatment of advanced kidney cancer. An EORTC and MRC study
- 15): Current opinion on the multi-disiplinary management of metastatic renal cell carcinoma and metastatic melanoma. Irish Society of Surgical Oncology. January 23, 2003. Dublin
- 16): 1st Eurolithiasis Society Congress (EULIS). Total stone management in the new millennium. Manshester, UK. 5-7 december 2002.
- 17) Uppsala Sygehus, Urologisk klinik. Study visit. Professor Per-Uno Malmstrøm to see fluroscense guided cystoskopy of patients with superficial bladder cancer. March 2003
- 18) Institute for Tumor Biology. Mater hospital. Brisbane, Australien. Januar 2004. Study visit regarding dendritic cells and vaccine treatment of cancer.
- 19): International Kidney Cancer Symposium. American Kidney Cancer Association. 12-14. november 2004. Chicago. USA.
- 20): Oncology consultant Tim Eisen, Royal Marsden Hospital, London. 2005. Study visit regarding immunological adjuvant treatment of kidney cancer. An EORTC and MRC study
- 21): The Scandinavian Association of Urology 27th congress June 10-13 2009, Reykjavik, Iceland
- 22) GU-ASCO, San Fransisco, USA. March 6-8, 2010

REFEREE ACTIVITY:

Journal of Urology 1997-1999
The Cancer Journal, France 1992-1993
Lung Cancer 1997

MEEMBERSHIPS:

Danishl Society of Urology
Danish association of pathology

European Association of Urology (EAU)
Danish Urological Science Club (DUSC)
American Assoc. of Cancer Research (AACR), corresponding membership 1992-98
Danish Society of Surgery
Danish Society of Cancer Research
Danish Medical Society